ZEVRA THERAPEUTICS, INC. (ZVRA) Form 10-Q — Nov 3, 2026
Zevra Therapeutics reported Q3 2026 revenue of $37.8 million, up roughly 45% from $26.1 million a year earlier, driven primarily by MIPLYFFA (arimoclomol) sales of $34.0 million for Niemann-Pick disease type C. The company swung to net income of $19.2 million ($0.26 diluted EPS) from a $0.5 million loss in Q3 2025, and repaid its full $63.1 million term loan in March 2026, leaving the balance sheet debt-free with $122.1 million in cash plus roughly $148.7 million in investments.
Key figures
- Eps
- 0.26
- Revenue
- 37756000
- Net Income
- 19208000
- Total Debt
- 0
- Revenue Yoy
- 44.9% increase vs Q3 2025 ($26.1M)
- Total Assets
- 313575000
- Cash Position
- 122148000
- Shares Outstanding
- 59504621
- Debt repaid
- $63.1M Credit Agreement repaid in full March 2026
- Eap revenue q3
- $3.6M net
- Olpruva q3 sales
- $0.2M
- Mipliffa q3 sales
- $34.0M (vs $22.4M in Q3 2025)
- Commave settlement
- $50.0M total; $43.3M gain on sale of SDX assets
- Nine month revenue
- $113.6M (vs $72.3M prior year)
- Investments current
- $73.4M
- Nine month net income
- $65.9M
- Investments noncurrent
- $75.3M
- Operating cash flow nine months
- $33.2M provided
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.